Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.
D. Slamon, G. Hortobagyi, D. Stroyakovskiy et al.· Annals of Oncology· 1 citation
The findings do not support a protective effect of GnRH antagonist treatment against cyclophosphamide-induced ovarian damage, and degarelix was associated with increased ovarian fibrosis in young mice treated with single-dose cyclophosphamide and failed to protect the ovarian reserve following either single or two dose...
Y. Lewis, Daniella Herszberg, Kate Fowler et al.· Frontiers in Endocrinology· 0 citations
Immunotherapy has revolutionized the therapeutic landscape for many cancers, but its application in solid tumors has lagged. There is now evidence that immunotherapy can improve outcomes in triple-negative breast cancer, but hormone receptor–positive (HR+) breast cancer has traditionally been considered immunologically...
J. Kay, J. Dixon-Douglas, M. Harris et al.· Journal of Clinical Investig...· 0 citations
A comprehensive analysis of 60 CIMs provides limited evidence supporting broad causal effects of circulating inflammatory markers contributing to variation in MD phenotypes, although most instruments demonstrated weak conditional instrument strength after inclusion of BMI.
A. H. Suger, T. Harrison, C. Haas et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.